A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis

OncoImmunology

Volumn 2, Issue 1, 2013, Pages

  Ma, Xinrong ^a   Holt, Dawn ^a   Kundu, Namita ^a,b   Reader, Jocelyn ^a   Goloubeva, Olga ^a   Take, Yukinori ^c   Fulton, Amy M ^a,b,d  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c RaQualia Pharma Inc   (Japan)

^d BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

EP4; Immunosuppression; Metastasis; NK cells; Prostaglandin E; Prostaglandin E receptor

Indexed keywords

7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; ADENYLATE CYCLASE; ANTINEOPLASTIC AGENT; PROSTAGLANDIN E RECEPTOR 4; RQ 15986; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER SURVIVAL; CELL PROTECTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVATION; FEMALE; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INNATE IMMUNITY; LUNG METASTASIS; MIGRATION INHIBITION; MOLECULAR DYNAMICS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

EID: 84886369650     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22647     Document Type: Article

References (30)

1. Holt D, Ma X, Kundu N, Fulton AM. Prostaglandin E(2) (PGE (2)) suppresses natural killer cell function primarily through the PGE(2) receptor EP4. Cancer Immunol Immunother 2011; 60:1577-86; PMID:21681369; http://dx.doi.org/10.1007/s00262-011-1064-9.
2. Holt DM, Ma X, Kundu N, Collin PD, Fulton AM. Modulation of host natural killer cell functions in breast cancer via prostaglandin E2 receptors EP2 and EP4. J Immunother 2012; 35:179-88; PMID:22306906; http://dx.doi.org/10.1097/CJI.0b013e318247a5e9.
3. Timoshenko AV, Xu G, Chakrabarti S, Lala PK, Chakraborty C. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Exp Cell Res 2003; 289:265-74; PMID:14499627; http://dx.doi.org/10.1016/S0014-4827(03)00269-6.
4. Robertson FM, Simeone A-M, Mazumdar A, Shah AH, McMurray JS, Ghosh S, et al. Molecular and pharmacological blockade of the EP4 receptor selectively inhibits both proliferation and invasion of human inflammatory breast cancer cells. J Exp Ther Oncol 2008; 7:299-312; PMID:19227010.
5. Robertson FM, Simeone A-M, Lucci A, McMurray JS, Ghosh S, Cristofanilli M. Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4. Cancer 2010; 116(Suppl):2806-14; PMID:20503412; http://dx.doi.org/10.1002/cncr.25167.
6. Ma X, Kundu N, Rifat S, Walser T, Fulton AM. Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res 2006; 66:2923-7; PMID:16540639; http://dx.doi.org/10.1158/0008-5472.CAN-05-4348.
7. Fulton AM, Ma X, Kundu N. Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res 2006; 66:9794-7; PMID:17047037; http://dx.doi.org/10.1158/0008-5472.CAN-06-2067.
8. Kundu N, Ma X, Holt D, Goloubeva O, Ostrand-Rosenberg S, Fulton AM. Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function. Breast Cancer Res Treat 2009; 117:235-42; PMID:18792778; http://dx.doi.org/10.1007/s10549-008-0180-5.
9. Ma X, Kundu N, Collin PD, Goloubeva O, Fulton AM. Frondoside A inhibits breast cancer metastasis and antagonizes prostaglandin E receptors EP4 and EP2. Breast Cancer Res Treat 2012; 132:1001-8; PMID:21761157; http://dx.doi.org/10.1007/s10549-011-1675-z.
10. Murase A, Taniguchi Y, Tonai-Kachi H, Nakao K, Takada J. In vitro pharmacological characterization of CJ-042794, a novel, potent, and selective prostaglandin EP(4) receptor antagonist. Life Sci 2008; 82:226-32; PMID:18155068; http://dx.doi.org/10.1016/j.lfs.2007.11.002.
11. Mamessier E, Sylvain A, Thibult M-L, Houvenaeghel G, Jacquemier J, Castellano R, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 2011; 121:3609-22; PMID:21841316; http://dx.doi.org/10.1172/JCI45816.
12. Oshima H, Hioki K, Popivanov K, Oguma K, Van Rooijen N, Ishikawa T-O, et al. Prostaglandin E2 signaling and bacterial infection recruit tumorpromoting macrophages to mouse gastric tumors. Gastroenterolology 2011; 140:596-607; PMID:21070778; http://dx.doi.org/10.1053/j.gastro.2010.11.007.
13. Kundu N, Yang Q, Dorsey R, Fulton AM. Increased cyclooxygenase-2 (cox-2) expression and activity in a murine model of metastatic breast cancer. Int J Cancer 2001; 93:681-6; PMID:11477578; http://dx.doi.org/10.1002/ijc.1397.
14. Balsamo M, Scordamaglia F, Pietra G, Manzini C, Cantoni C, Boitano M, et al. Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. Proc Natl Acad Sci U S A 2009; 106:20847-52; PMID:19934056; http://dx.doi.org/10.1073/pnas.0906481106.
15. Eruslanov E, Daurkin I, Ortiz J, Vieweg J, Kusmartsev S. Pivotal Advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE2 catabolism in myeloid cells. J Leukoc Biol 2010; 88:839-48; PMID:20587738; http://dx.doi.org/10.1189/jlb.1209821.
16. Pietra G, Manzini C, Rivara S, Vitale M, Cantoni C, Petretto A, et al. Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity. Cancer Res 2012; 72:1407-15; PMID:22258454; http://dx.doi.org/10.1158/0008-5472.CAN-11-2544.
17. Basu GD, Tinder TL, Bradley JM, Tu T, Hattrup CL, Pockaj BA, et al. Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO. J Immunol 2006; 177:2391-402; PMID:16888001.
18. Muller AJ, Prendergast GC. Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets 2007; 7:31-40; PMID:17305476; http://dx.doi.org/10.2174/156800907780006896.
19. Reader JC, Holt D, Fulton AM. Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer Metastasis Rev 2011; 30:449-63; PMID:22002714; http://dx.doi.org/10.1007/s10555-011-9303-2.
20. Chell SD, Witherden IR, Dobson RR, Moorghen M, Herman AA, Qualtrough D, et al. Increased EP4 receptor expression in colorectal cancer progression promotes cell growth and anchorage independence. Cancer Res 2006; 66:3106-13; PMID:16540660; http://dx.doi.org/10.1158/0008-5472.CAN-05-3702.
21. Hawcroft G, Ko CWS, Hull MA. Prostaglandin E2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cells. Oncogene 2007; 26:3006-19; PMID:17130837; http://dx.doi.org/10.1038/sj.onc.1210113.
22. Chandramouli A, Onyeagucha BC, Mercado-Pimentel ME, Stankova L, Shahin NA, LaFleur BJ, et al. MicroRNA-101 (miR-101) post-transcriptionally regulates the expression of EP4 receptor in colon cancers. Cancer Biol Ther 2012; 13:175-83; PMID:22353936; http://dx.doi.org/10.4161/cbt.13.3.18874.
23. Cherukuri DP, Chen XBO, Goulet A-C, Young RN, Han Y, Heimark RL, et al. The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells. Exp Cell Res 2007; 313:2969-79; PMID:17631291; http://dx.doi.org/10.1016/j.yexcr.2007.06.004.
24. George RJ, Sturmoski MA, Anant S, Houchen CW. EP4 mediates PGE2 dependent cell survival through the PI3 kinase/AKT pathway. Prostaglandins Other Lipid Mediat 2007; 83:112-20; PMID:17259077; http://dx.doi.org/10.1016/j.prostaglandins.2006.10.005.
25. Zheng Y, Ritzenthaler JD, Sun X, Roman J, Han S-W. Prostaglandin E2 stimulates human lung carcinoma cell growth through induction of integrin-linked kinase: the involvement of EP4 and Sp1. Cancer Res 2009; 69:896-904; PMID:19176380; http://dx.doi.org/10.1158/0008-5472.CAN-08-2677.
26. Jain S, Chakraborty G, Raja R, Kale S, Kundu GC. Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res 2008; 68:7750-9; PMID:18829529; http://dx.doi.org/10.1158/0008-5472.CAN-07-6689.
27. Terada N, Shimizu Y, Kamba T, Inoue T, Maeno A, Kobayashi T, et al. Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model. Cancer Res 2010; 70:1606-15; PMID:20145136; http://dx.doi.org/10.1158/0008-5472.CAN-09-2984.
28. Subbaramaiah K, Hudis C, Chang S-H, Hla T, Dannenberg AJ. EP2 and EP4 receptors regulate aromatase expression in human adipocytes and breast cancer cells. Evidence of a BRCA1 and p300 exchange. J Biol Chem 2008; 283:3433-44; PMID:18083712; http://dx.doi.org/10.1074/jbc.M705409200.
29. Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN. Role of β-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci U S A 2006; 103:1492-7; PMID:16432186; http://dx.doi.org/10.1073/pnas.0510562103.
30. Yang L, Huang Y, Porta R, Yanagisawa K, Gonzalez A, Segi E, et al. Host and direct antitumor effects and profound reduction in tumor metastasis with selective EP4 receptor antagonism. Cancer Res 2006; 66:9665-72; PMID:17018624; http://dx.doi.org/10.1158/0008-5472.CAN-06-1271.